In this episode Dr Harry Gibbs, from The Alfred Hospital in Victoria and Dr Ander Cohen from Guy’s and St Thomas’ Hospital, King’s College in London, UK discuss stroke prevention with DOACs in patients with chronic kidney disease. They talk about how often renal function should be monitored, and how to manage falling creatinine clearance levels in the face of an increased risk of stroke, and increased bleeding risk, as a result of the kidney disease .

ELIQUIS® (apixaban)

PBS Information: Authority required (STREAMLINED) Refer to PBS Schedule for full authority information.

PBS Codes: NVAF – 4269 and DVT/Pe initial treatment – 4298 (DVT); 5098 (PE). Other PBS codes differ – please refer to PBS Schedule.

NVAF: Non-valvular atrial fibrillation; DVT: Deep vein thrombosis; PE: Pulmonary embolism.

Before prescribing, please review full ELIQUIS Product Information available from Bristol Myers Squibb Australia by calling 1800 067 567

Please note that apixaban is contraindicated in patients with creatine clearance levels less than 25 mL/min. 

ELIQUIS Consumer Medical Information

ELIQUIS Product Information

Reference

1. Cohen AT, Sah J, Dhamane AD et al. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease. Thromb Haemost 2021. doi: 10.1055/s-0041-1740254. Epub ahead of print. 

t360 is an educational program supported by Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave VIC 3170 and Pfizer Australia Pty Ltd, ABN 50 008 422 348, 151 Clarence Street, Level 15–18, Sydney NSW 2000, and developed by Elixir Healthcare Education Pty Limited, ABN 36 092 185 665, Level 32, 101 Miller Street, North Sydney NSW 2060. ©Copyright 2022 Bristol Myers Squibb–Pfizer Alliance and Elixir Healthcare Education Pty Limited. PP-ELI-AUS-1093.